How Technology Can Reduce Pharmacy Staff Burnout
Drug Topics
NOVEMBER 5, 2024
Companies like ShiftRx are using technology to help solve the staffing shortage crisis in health care.
November, 2024
567 
Turning Loss into Purpose: My Journey to a Pharmacy Career to Make a Difference
Pharmacy Is Right For Me
NOVEMBER 4, 2024
Meet Lila, a passionate fourth-year Pharm.D. student at Auburn University Harrison College of Pharmacy. During her APPE rotation with the American Association of Colleges of Pharmacy , Lila opened up about her inspiring journey to find the perfect pharmacy school and how, with the guidance of mentors, she discovered her true “Pharmily.” How did you choose your pharmacy school/college or graduate program?
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
5 Ways To Celebrate Antibiotic Awareness Week 2024
IDStewardship
NOVEMBER 18, 2024
This article discusses ways to celebrate the annual observance of antibiotic awareness week 2024. Written by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP Each year for one week the United States Centers for Disease Control and Prevention (CDC) observes U.S. Antibiotic Awareness Week (USAAW) and encourages others to participate in the event. The USAAW theme this year is “Fighting Antibiotic Resistance Takes All Of Us.” This same week the World Health Organization observes World Antimic
STAT+: AI in drug discovery is ‘nonsense,’ but call Schrödinger ‘AI’ if you want, says CEO
STAT
NOVEMBER 20, 2024
Schrödinger CEO Ramy Farid wants you to know that his company isn’t an AI company…but he’ll call it that if you want to. The company, founded in 1990, started out by making software that used the basic laws of physics to laboriously and exactly predict how molecules will interact with each other in space. Those calculations, rooted in the field of computational physics, needed lots of expensive and time-consuming computing power to run, and many people abandoned those t
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Spravato is just the beginning in a new wave of depression meds
PharmaVoice
NOVEMBER 11, 2024
Psychiatry is getting more targeted as drugmakers develop a new range of treatments for depression.
How cinnamon lowers blood sugar
The Checkup by Singlecare
NOVEMBER 4, 2024
Diabetes is a medical condition that occurs when your body can’t regulate blood sugar levels. Consistently elevated blood sugar causes health problems, such as heart disease, kidney disease, and nerve damage, particularly in your feet and eyes. Diabetes treatment usually includes medications , such as oral medications, non-insulin injectable medicines, and sometimes insulin , depending on which type of diabetes you have as well as your blood glucose control.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Novo Nordisk's semaglutide delivers in phase 3 MASH study, teeing up filings
Fierce Pharma
NOVEMBER 1, 2024
With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semagluti | Novo Nordisk on Friday revealed that its star GLP-1 semaglutide met the mark in a late-stage MASH study. The positive results build on the thesis that GLP-1s could become a foundational piece in the treatment paradigm for the fatty liver disease, according to analysts at William Blair.
J&J seek approval for first drug to treat high-risk smoldering myeloma
Pharmafile
NOVEMBER 13, 2024
Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and Drug Agency (FDA) and the European Medicines agency (EMA) for the approval of a new indication for DARAZALEX FASPRO (daratumumab and hyluronidase-fihj). DARAZLEX FASPRO would be used as a monotherapy for the treatment of high-risk smoldering multiple myeloma in adult […] The post J&J seek approval for first drug to treat high-risk smoldering myeloma appeared first on Pharmafile.
STAT+: It might be now or never for the BIOSECURE Act
STAT
NOVEMBER 27, 2024
WASHINGTON — Legislation targeting Chinese biotechnology companies caused a ruckus early this year. None of that may matter if Congress doesn’t pass it in December. The BIOSECURE Act would restrict U.S. pharmaceutical and biotechnology companies from doing business with certain Chinese companies, including WuXi AppTec and WuXi Biologics.
CEO with type 1 diabetes works to deliver ‘world’s first’ functional cure
PharmaVoice
NOVEMBER 5, 2024
Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Does Adderall affect sleep?
The Checkup by Singlecare
NOVEMBER 19, 2024
Adderall is a controlled prescription medication commonly used to treat attention deficit hyperactivity disorder ( ADHD ). It is also approved by the Food and Drug Administration (FDA) to promote wakefulness in people with narcolepsy , a sleep disorder. The standard, immediate-release Adderall is usually taken two or three times per day, while extended-release Adderall XR is taken once daily.
Q&A: The Future of Biosimilar Pricing at the Pharmacy Counter
Drug Topics
NOVEMBER 30, 2024
Steve Callahan, Senior Director of Advisory & Insights at MMIT, discussed out-of-pocket costs and the impact biosimilars are predicted to have for patients in the future.
AstraZeneca shares tumble after reports China unit is linked to insurance fraud
The Guardian - Pharmaceutical Industry
NOVEMBER 5, 2024
Pharmaceutical’s weight loss pill described as ‘underwhelming’, also piling pressure on share price AstraZeneca shares tumbled on Tuesday wiping £14bn off the value of Britain’s biggest drug maker, after a report that dozens of senior executives at its China unit could be implicated in an insurance fraud case in the country’s pharmaceutical sector. Also putting pressure on the share price, early data on AstraZeneca’s experimental weight loss pill published on Monday was described as “somewhat un
Sanofi lays out €40M to beef up transplant, diabetes drug production in France
Fierce Pharma
NOVEMBER 18, 2024
With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in a bid to boost production for a long-approved transplant treatment and a | Sanofi has unveiled a 40 million euro investment at its Lyon Gerland biomanufacturing site in France. The cash infusion will help bolster local production of the company’s polyclonal antibody Thymoglubulin for kidney transplant rejection, as well as expected future capacity needs for the type 1 diab
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
What really happens to drug prices when patents expire
STAT
NOVEMBER 4, 2024
This is Part 5 of “Behind the Counter,” an in-depth video series demystifying the complex world of patents and drug pricing. When patents for name brand medicines expire, the price of that medicine drops significantly as generic versions enter the market. Lower prices are good news for patients seeking more affordable medications, but the change can sometimes take a while.
Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals
PharmaVoice
NOVEMBER 21, 2024
A subcutaneous version of Merck’s Keytruda was as effective as the infused version in a late-stage study, but the company won’t be the first to market.
Can you take trazodone and Lexapro?
The Checkup by Singlecare
NOVEMBER 11, 2024
Finding the right medication to manage a mental health condition is difficult, and it can take some trial and error to settle on an effective treatment plan. Two commonly prescribed medications for various mental health conditions are trazodone and Lexapro. As a brand-name prescription drug, Lexapro is FDA -approved to treat major depressive disorder and anxiety disorders.
H5N1 Bird Flu: A Slowly Looming Public Health Threat
Drug Topics
NOVEMBER 22, 2024
Public health and infectious disease experts offered their perspectives on the 2024 US bird flu outbreak and its potential of becoming a greater public health crisis.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development
The FDA Law Blog
NOVEMBER 10, 2024
By Sarah Wicks & James E. Valentine — The U.S. Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field.
MSD joins PD-1/VEGF push in cancer with LaNova deal
pharmaphorum
NOVEMBER 14, 2024
There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn't left behind. Its solution is a licensing deal with Chinese biotech LaNova Medicines for LM-299, which consists of an anti-VEGF antibody joined to the functional parts of a pair of anti-PD-1 antibodies.
STAT+: How Pfizer used wearables to tap into the promise of an experimental drug
STAT
NOVEMBER 12, 2024
Pfizer’s promising research on a treatment for a dangerous cancer-related condition is also helping prove out the value of wearables in clinical trials. In September, the pharma giant reported results showing that an experimental antibody could positively impact people with cachexia, a complication sometimes called “wasting syndrome” that can cause people with cancer to lose weight and make it harder for them to tolerate treatments.
An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond
PharmaVoice
NOVEMBER 26, 2024
Stoke Therapeutics is entering phase 3 with its RNA medicine designed to treat a rare epileptic condition.
4 vitamins for post-COVID fatigue
The Checkup by Singlecare
NOVEMBER 26, 2024
When you’re sick with a viral infection, you expect to feel poorly for a few days. COVID is no exception. Whether you’re hit with respiratory, GI, or flu-like symptoms such as muscle pain, headache, and fatigue, testing positive for COVID means being down for the count for a bit before returning to your daily routine. However, what if you don’t bounce back, even after you’re technically recovered?
Two Independent Pharmacies Latest to Sue Major PBMs
Drug Topics
NOVEMBER 5, 2024
A collection of independent pharmacies was the next in line to file suits against major pharmacy benefit managers for alleged drug price fixing.
European Pharmaceutical Review Issue 5 2024
European Pharmaceutical Review
NOVEMBER 21, 2024
Articles in Issue 5 of European Pharmaceutical Review include: FOREWORD ICH Q6(R1): test criteria and specifications Dave Elder David P Elder Consultancy CELL & GENE THERAPY How automation and digital technologies will unlock the full potential of advanced therapies Dr Stephen Ward CGT Catapult Hydrogel encapsulation: unlocking the potential of cell therapies for targeted treatments Dr Stephen Harrington and Francis Karanu Likarda SUSTAINABILITY Transitioning to digital product information t
IVIG Demonstrates Effectiveness in Several Neuroimmune Conditions, Indicating Potential for Long COVID Treatment
Pharmacy Times
NOVEMBER 23, 2024
Intravenous immunoglobulin (IVIG) has proven efficacy in autoimmune neuropathies, with mixed but promising outcomes in severe COVID-19 cases and post-acute sequelae of SARS-CoV-2 infection trials.
Opinion: The FDA’s risky action on compounding weight loss drugs
STAT
NOVEMBER 19, 2024
When Makena, a drug designed to prevent preterm births, hit the market in 2011 at $1,500 per dose, it drew rife backlash. The drug was based on an active ingredient that had been available for many years at a much lower cost. Confronted with the public outcry, the FDA took an unusual step: It allowed pharmacies to continue making their own copies of the drug through the practice of pharmacy compounding, selling it at a fraction of Makena’s price.
What RFK Jr.’s influence could mean for pharma
PharmaVoice
NOVEMBER 8, 2024
Past comments hint at the changes Robert F. Kennedy Jr. could make across the various sectors of healthcare.
Can you drink on Zepbound?
The Checkup by Singlecare
NOVEMBER 15, 2024
No matter the time of year, there’s always a family get-together, wedding celebration, or festive party just waiting to sabotage your weight loss goals—with delicious treats and alcoholic beverages. If you’re taking Zepbound (tirzepatide), there’s an added layer to consider besides the extra calories: Is it safe to drink while taking this medication?
Medication Optimization Needed for Patients with Long COVID
Drug Topics
NOVEMBER 19, 2024
Investigators said there is an imperative to optimize medication utilization and explore the consequences of medication burden on treatment outcomes in patients with long COVID.
Pay Per Click Essentials for Pharma Marketing Executives: A Beginner’s Guide
Pharma Marketing Network
NOVEMBER 15, 2024
In today’s digital-first world, Pay Per Click (PPC) advertising has become an essential strategy for pharma marketing executives. Imagine having a tool that allows you to target specific audiences actively searching for healthcare solutions, like branded medications or treatment options. PPC does just that. But how does it work, and how can you make the most of it in the competitive pharmaceutical industry?
After US plant reveal, France's Orano Med lays out €250M to build another radioligand facility overseas
Fierce Pharma
NOVEMBER 15, 2024
With multiple drugmakers already announcing a slew of radiopharmaceutical moves this year, France’s Orano Med is doubling down on the nuclear medicine craze. | Orano Med—developing targeted alpha therapies for cancer—kicked off construction of a 250 million euro plant in the Bessines-sur-Gartempe commune of France. Dubbed the Advanced Thorium Extraction Facility, the new 7,000-square-meter site is slated to manufacture thorium-228, a precursor of lead-212, for radioligand therapies.
STAT+: Novo’s earnings report sends shares up, as obesity drug sales show continued growth
STAT
NOVEMBER 6, 2024
LONDON — Sales of Novo Nordisk’s obesity drug Wegovy jumped in the third quarter, the company said Wednesday as it reported quarterly profits that were in line with analyst expectations. Novo’s third quarter performance will be seen as a win for the company, particularly after Eli Lilly — its rival in the booming obesity drug market — reported earnings last week that fell below forecasts.
Let's personalize your content